Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 5:44 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 920 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Hepatitis C Virus (HCV) Clear all
Recruiting Not applicable Interventional

Hepatitis C Pharmacist, Physician, Patient Navigator Collaborative Care Model in Permanent Supportive Housing

NCT07667101
View directory record Official record
Conditions
HEPATITIS C (HCV)
Interventions
PPP-CCM
Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
444 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 24, 2026 · Synced Oct 14, 2026, 5:44 AM EDT
Completed Phase 2 Interventional Results available

Study of Daclatasvir (BMS-790052) Add-on to Standard of Care in Treatment- naïve Patients

NCT01125189
View directory record Official record
Conditions
Hepatitis C Virus
Interventions
Daclatasvir, Placebo, peg-interferon alfa-2a, ribavirin
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 70 Years
Enrollment
558 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
33
States / cities
Montgomery, Alabama • La Jolla, California • Los Angeles, California + 26 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2015 · Synced Oct 14, 2026, 5:44 AM EDT
Completed No phase listed Observational

A Study to Examine Patient Characteristics, Health Care Management and Health Outcomes of Hepatitis C Virus (HCV) Patients Treated With Simeprevir

NCT02103699
View directory record Official record
Conditions
Hepatitis C Virus
Interventions
No intervention
Drug
Lead sponsor
Janssen Scientific Affairs, LLC
Industry
Eligibility
18 Years and older
Enrollment
315 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
32
States / cities
Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 29 more
Source: ClinicalTrials.gov public record
Updated Feb 22, 2016 · Synced Oct 14, 2026, 5:44 AM EDT
Completed Phase 4 Interventional Results available

Renal Transplants in Hepatitis C Negative Recipients With Nucleic Acid Positive Donors

NCT03627299
View directory record Official record
Conditions
End Stage Renal Disease, Hepatitis C
Interventions
300mg glecaprevir/pibrentasivir 120mg
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
40 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 19, 2021 · Synced Oct 14, 2026, 5:44 AM EDT
Completed Early Phase 1 Interventional

A Single-center Pilot Study Evaluating a Preemptive Short Course of Glecaprevir/Pibrentasvir in Hepatitis C Positive to Negative Kidney Transplantation

NCT04682509
View directory record Official record
Conditions
ESRD
Interventions
Glecaprevir/pibrentasvir
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 99 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 25, 2024 · Synced Oct 14, 2026, 5:44 AM EDT
Completed Phase 2 Interventional Results available

Combination Therapy for Chronic Hepatitis C Infection

NCT01805882
View directory record Official record
Conditions
Hepatitis C, Chronic
Interventions
Sofosbuvir, Ledipasvir, GS-9669, GS-9451
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
229 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
3
States / cities
Washington D.C., District of Columbia • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 8, 2017 · Synced Oct 14, 2026, 5:44 AM EDT
Completed Phase 4 Interventional Results available

Study to Evaluate the Safety and Efficacy of Daclatasvir/Sofosbuvir/Ribavirin for 16 Versus 24 Weeks for HCV Genotype 3 Cirrhotics

NCT02304159
View directory record Official record
Conditions
Hepatitis C, Cirrhosis
Interventions
daclatasvir, Sofosbuvir, Sovaldi, Ribavirin
Drug
Lead sponsor
Tarek I. Hassanein, M.D., FACP, FAG, AGAF
Other
Eligibility
18 Years to 75 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Coronado, California
Source: ClinicalTrials.gov public record
Updated Apr 24, 2019 · Synced Oct 14, 2026, 5:44 AM EDT
Not yet recruiting No phase listed Observational Accepts healthy volunteers

Assessing Performance of a Hepatitis C Emergency Department (HepC-EnD) Screening Tool: IT Integration Process for Electronic Health Record System

NCT07406490
View directory record Official record
Conditions
Hepatitis C Virus (HCV), Hepatitis C Virus (HCV) Infection, HIV (Human Immunodeficiency Virus)
Interventions
Physician-Initiated Screening (Conventional Screening), FOCUS (Universal Screening), HepC-EnD (Targeted Screening)
Other
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 79 Years
Enrollment
6,466 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
3
States / cities
Gainesville, Florida • Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Oct 14, 2026, 5:44 AM EDT
Completed Phase 4 Interventional Results available

Effects of Ledipasvir/Sofosbuvir on the Pharmacokinetics and Renal Safety of Tenofovir Alafenamide (TAF)

NCT03126370
View directory record Official record
Conditions
Hepatitis C, HIV Coinfection
Interventions
TDF with a boosted protease inhibitor, TAF with a boosted protease inhibitor, TAF with a boosted protease inhibitor and LDV/SOF
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 70 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 11, 2021 · Synced Oct 14, 2026, 5:44 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Community-Based, Client-Centered Prevention Homes to Address the Rural Opioid Epidemic- Aim 3

NCT04268173
View directory record Official record
Conditions
Drug Use Disorders, Hepatitis C, Harm Reduction, Opioid-use Disorder
Interventions
Community-Based, Client-Centered Prevention Home
Other
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
343 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
6
States / cities
Appleton, Wisconsin • Eau Claire, Wisconsin • Green Bay, Wisconsin + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2024 · Synced Oct 14, 2026, 5:44 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Multiple Doses of ABT-333 Alone and in Combination With Pegylated Interferon (pegIFN) and Ribavirin (RBV) in Subjects With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection

NCT00851890
View directory record Official record
Conditions
Chronic Hepatitis C Virus Infection
Interventions
ABT-333, Placebo for ABT-333, Pegylated interferon, Ribavirin
Drug · Other
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Eligibility
18 Years to 70 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
7
States / cities
Anaheim, California • Los Angeles, California • Orlando, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2018 · Synced Oct 14, 2026, 5:44 AM EDT
Withdrawn Phase 1 Interventional

TG4040 in Patients With Chronic HCV

NCT00449124
View directory record Official record
Conditions
Hepatitis C
Interventions
Placebo, TG4040
Drug · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2007
U.S. locations
2
States / cities
St Louis, Missouri • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 23, 2019 · Synced Oct 14, 2026, 5:44 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Characterization of Clonal B Cell Populations in HCV Infection

NCT00435201
View directory record Official record
Conditions
Hepatitis C
Interventions
Not listed
Lead sponsor
Rockefeller University
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 9, 2013 · Synced Oct 14, 2026, 5:44 AM EDT
Completed Phase 4 Interventional Results available

Kidney Transplants in Hepatitis C Negative Recipients With Hepatitis C Viremic Donors

NCT04575896
View directory record Official record
Conditions
End Stage Renal Disease, Hepatitis C
Interventions
Glecaprevir/pibrentasvir
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 10, 2024 · Synced Oct 14, 2026, 5:44 AM EDT
Withdrawn Phase 2 Interventional

A Study of BMS-824393 in Combination With Peginterferon Alfa-2a (Pegasys) and Ribavirin (Copegus) in Treatment Naive Subjects With Chronic Hepatitis C Virus Genotype I

NCT01142700
View directory record Official record
Conditions
Chronic Hepatitis C Virus Genotype 1
Interventions
BMS-824393, Placebo, Peginterferon Alpha-2a, Ribavirin
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
11
States / cities
Coronado, California • San Diego, California • Washington D.C., District of Columbia + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2011 · Synced Oct 14, 2026, 5:44 AM EDT
Completed No phase listed Observational

Correlation of Hepatitis C, Alcoholic Liver Disease, and Renal Failure With Hyperfibrinolysis in Liver Failure

NCT02737345
View directory record Official record
Conditions
Cirrhosis
Interventions
Rotem
Other
Lead sponsor
Scott Allen
Other
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Nov 8, 2017 · Synced Oct 14, 2026, 5:44 AM EDT
Terminated Phase 4 Interventional Results available

Telaprevir, Peg-IFN-alfa-2a, and RBV in Treatment-Experienced Black/African American and Non-Black/African American Subjects With Genotype 1 Chronic Hepatitis C

NCT01467492
View directory record Official record
Conditions
Hepatitis C
Interventions
Telaprevir, Ribavirin, Pegylated Interferon Alfa-2a
Drug · Biological
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 70 Years
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
27
States / cities
Birmingham, Alabama • San Francisco, California • New Haven, Connecticut + 24 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2015 · Synced Oct 14, 2026, 5:44 AM EDT
Completed Phase 2 Interventional

CPG10101 Combination Therapy For The Treatment Of Hepatitis C In Non-Responder (Null And Partial Responder) Hepatitis C Virus (HCV) Genotype 1 Infected Subjects

NCT00277238
View directory record Official record
Conditions
Hepatitis, Chronic Active
Interventions
CPG10101, Control
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
14
States / cities
Chicago, Illinois • Indianapolis, Indiana • New Orleans, Louisiana + 11 more
Source: ClinicalTrials.gov public record
Updated Mar 8, 2017 · Synced Oct 14, 2026, 5:44 AM EDT
Withdrawn No phase listed Observational

SIMpill Medication Dispensing Device in the Treatment of HCV

NCT01691235
View directory record Official record
Conditions
Chronic Hepatitis C Virus
Interventions
SIMpill device
Device
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 8, 2014 · Synced Oct 14, 2026, 5:44 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

The Hepatitis C Transplant Collaborative

NCT04493385
View directory record Official record
Conditions
Transplant; Failure, Heart, Hepatitis C
Interventions
Not listed
Lead sponsor
Baylor Research Institute
Other
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2030
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Oct 14, 2026, 5:44 AM EDT
Completed Phase 1Phase 2 Interventional

Valopicitabine When Administered Alone and in Combination With Interferon to Treatment-Naive Patients With Hepatitis C

NCT00120835
View directory record Official record
Conditions
Chronic Hepatitis C
Interventions
valopicitabine, pegylated interferon
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 65 Years
Timeline
Started 2004
U.S. locations
2
States / cities
Bradenton, Florida • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 10, 2010 · Synced Oct 14, 2026, 5:44 AM EDT
Terminated Phase 3 Interventional Results available

Eltrombopag To Reduce The Need For Platelet Transfusion In Subjects With Chronic Liver Disease And Thrombocytopenia Undergoing Elective Invasive Procedures

NCT00678587
View directory record Official record
Conditions
Non-alcoholic Steatohepatitis, Chronic Liver Disease, HCV, NASH - Nonalcoholic Steatohepatitis, HIV Infection, Thrombocytopenia, Hepatitis C Virus, HBV, Human Immunodeficiency Virus, Liver Diseases, Hepatitis B Virus
Interventions
Eltrombopag, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
292 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
33
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 28 more
Source: ClinicalTrials.gov public record
Updated Oct 12, 2018 · Synced Oct 14, 2026, 5:44 AM EDT
Completed Phase 1 Interventional

The Effects of IL-1 Blockade on Inotrope Sensitivity in Patients With Heart Failure (AID-HEART)

NCT06062966
View directory record Official record
Conditions
Heart Failure
Interventions
Anakinra
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
21 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Oct 14, 2026, 5:44 AM EDT
Terminated Phase 2 Interventional

A Safety and Efficacy Study of the Combination of VX-222 and Telaprevir in Treatment-Naïve Subjects With Genotype 1 Chronic Hepatitis C Virus Infection

NCT01080222
View directory record Official record
Conditions
Chronic Hepatitis C Virus Infection
Interventions
telaprevir, VX-222, ribavirin, peginterferon-alfa-2a
Drug · Biological
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 65 Years
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
19
States / cities
La Jolla, California • San Francisco, California • Aurora, Colorado + 16 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2020 · Synced Oct 14, 2026, 5:44 AM EDT